DAX21.727 +0,4%ESt505.282 +1,0%Top 10 Crypto16,75 +6,2%Dow44.698 ±-0,0%Nas19.632 ±0,0%Bitcoin101.147 +1,6%Euro1,0394 -0,3%Öl76,93 ±-0,0%Gold2.794 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Tesla A1CX3T Microsoft 870747 Deutsche Bank 514000 Siemens Energy ENER6Y Rheinmetall 703000 Deutsche Telekom 555750 Meta Platforms (ex Facebook) A1JWVX Bayer BAY001 Mercedes-Benz Group (ex Daimler) 710000 Apple 865985 Amazon 906866 RENK RENK73 Daimler Truck DTR0CK BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
EZB senkt Zinsen: Wall Street fester -- DAX schließt im Plus - neuer Rekord bei 21.700 Punkte-Marke geknackt -- Deutsche Bank mit Gewinneinbruch -- Microsoft, Tesla, STMicro, BVB, VW, Meta im Fokus
Top News
Wie sich der Euro nach dem EZB-Zinsentscheid bewegt Wie sich der Euro nach dem EZB-Zinsentscheid bewegt
Rohstoffe: Aktueller Marktbericht zu Gold, Öl & Co. Rohstoffe: Aktueller Marktbericht zu Gold, Öl & Co.
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Nur noch 1 Tag: Sichere Dir jetzt noch Deinen Mega-Bonus - Jetzt informieren!

Pfizer Aktie

NeuKaufenVerkaufen
Pfizer Aktien-Sparplan
25,75 EUR +0,14 EUR +0,55 %
STU
26,73 USD +0,12 USD +0,43 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.144,75 Mrd. EUR

KGV76,67Div. Rendite5,73%

WKN852009

ISINUS7170811035

SymbolPFE

Pfizer Aktien News

DatumMeistgelesen
BusinesswirePfizer Declares Fourth-Quarter 2022 Dividend
BusinesswirePfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries
BusinesswirePfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts
BusinesswirePfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
BusinesswirePfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
BusinesswirePfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
BusinesswirePfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
PR NewswireStrata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer
BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
BusinesswireFDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
BusinesswireFDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women
BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
BusinesswirePfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action
MyDividendsPfizer schüttet 335. vierteljährliche Dividende in Folge aus
BusinesswirePfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
BusinesswirePfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
PR NewswirePFIZER RANKED LEADING COMPANY IN ASIA FOR COVID-19 RESPONSE AND PATIENT-CENTRIC APPROACH BY ASIAN PATIENT GROUPS
BusinesswirePfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
BusinesswirePfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
BusinesswirePfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
BusinesswirePfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
BusinesswirePfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
BusinesswirePfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
BusinesswirePFIZER REPORTS SECOND-QUARTER 2022 RESULTS
RSSGeneral statement of acquisition of beneficial ownership
BusinesswirePfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
BusinesswirePfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
RSSStatement of acquisition of beneficial ownership by individuals
BusinesswireRoivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
RSSStatement of acquisition of beneficial ownership by individuals
BusinesswirePfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
BusinesswirePfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
MyDividendsPfizer gibt 335. vierteljährliche Dividende in Folge bekannt
BusinesswirePfizer Declares Third-Quarter 2022 Dividend
BusinesswireValneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
BusinesswirePfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
BusinesswirePfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
Wer­bung

Pfizer News

Pfizer News: auf dieser Seite finden Sie alle Pfizer News und Nachrichten zur Pfizer Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pfizer News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pfizer News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.